Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.00 is 135% below its 5-year average of -0.43, near the low end of its 5-year range (-1.00–-0.01).
29.87% below its 12-month average of -0.77.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.23.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.00
EARNINGS PER SHARE (EPS) AVG TTM
-0.77
EARNINGS PER SHARE (EPS) AVG 3Y
-0.59
EARNINGS PER SHARE (EPS) AVG 5Y
-0.43
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.87%
CURRENT VS 3Y AVG
-69.49%
CURRENT VS 5Y AVG
-134.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GH Research PLC
Market Cap
$1.49B
Earnings Per Share (EPS)
-1.00
TTM Avg
-0.77
3Y Avg
-0.59
5Y Avg
-0.43
Market Cap
$1.50B
Earnings Per Share (EPS)
0.38
TTM Avg
-0.16
3Y Avg
-0.18
5Y Avg
-0.35
Market Cap
$1.46B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.53B
Earnings Per Share (EPS)
4.10
TTM Avg
2.19
3Y Avg
2.59
5Y Avg
2.64
Market Cap
$1.47B
Earnings Per Share (EPS)
1.71
TTM Avg
0.68
3Y Avg
0.58
5Y Avg
0.72
Market Cap
$1.46B
Earnings Per Share (EPS)
-2.74
TTM Avg
-3.05
3Y Avg
-2.66
5Y Avg
-2.66
Market Cap
$1.54B
Earnings Per Share (EPS)
-0.44
TTM Avg
-0.04
3Y Avg
-0.09
5Y Avg
-0.12
Market Cap
$1.43B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.40B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.49B | -1.00 | -0.77 | -0.59 | -0.43 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 0.38 | -0.16 | -0.18 | -0.35 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 4.10 | 2.19 | 2.59 | 2.64 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 1.71 | 0.68 | 0.58 | 0.72 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -2.74 | -3.05 | -2.66 | -2.66 |
| Certara, Inc. (CERT)vs › | $1.54B | -0.44 | -0.04 | -0.09 | -0.12 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 5.37 | -2.79 | -4.06 | -3.18 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -8.88 | 53.77 | 24.70 | 19.33 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.37B | N/A | -1.26 | -1.26 | -1.26 |
Trailing EPS (TTM)
$-1.00
Forward EPS (Est.)
$-1.19
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.79 |
| 2024-12-31 | -0.75 |
| 2023-12-31 | -0.68 |
| 2022-12-31 | -0.14 |
| 2021-12-31 | -0.18 |
| 2020-12-31 | -0.01 |
| 2019-12-31 | -0.01 |
